Pharmaceutical companies are launching new oral GLP-1 pills and next-generation injectables to intensify competition in the obesity-drug market [1, 2].
This shift represents a critical evolution in weight-loss treatment, moving beyond the initial wave of injectables to offer patients more convenient delivery methods and potentially higher efficacy rates.
At the American Diabetes Association (ADA) scientific session in New Orleans this month [4], industry leaders including Novo Nordisk, Eli Lilly, Structure Therapeutics, and Zealand Pharma showcased a new pipeline of therapies [1, 3]. The current landscape arrives five years after the FDA approved Wegovy in 2021 [1].
Competition is now centering on oral formulations and combination therapies to reach a broader patient base [3]. Novo Nordisk and Eli Lilly both introduced oral GLP-1 obesity pills in 2026 [1].
"We’re seeing a crowded field of GLP-1 candidates, and the next wave will focus on oral formulations and combination therapies," Angelica Peebles said [3].
Eli Lilly provided new data on its injectable candidate, retatrutide. Researchers said retatrutide matches bariatric surgery in weight-loss outcomes, according to data presented at ADA 2026 [5].
Beyond weight loss, the company is targeting related comorbidities. A Lilly spokesperson said that in a Phase 3 trial, a weekly injection of retatrutide reduced moderate-to-severe obstructive sleep apnea severity by 60.6 percent in adults with obesity [6].
These advancements are driven by rapid market growth and unmet patient needs [2]. Drugmakers are prioritizing these next-generation therapies to secure market share as the industry moves toward more accessible, non-invasive options [2, 3].
“Retatrutide matches bariatric surgery in weight-loss outcomes, according to data presented at ADA 2026.”
The transition from injectable-only treatments to oral pills lowers the barrier to entry for millions of patients, likely increasing the total addressable market for GLP-1 drugs. Furthermore, by targeting comorbidities like sleep apnea and matching the results of invasive bariatric surgery, these therapies are positioning themselves as primary medical interventions rather than just supplementary weight-loss aids.
